Payment overview · 2025
General Payments
$59.76
3 reported records · 2 companies
Healthcare provider profile · identity verified
Michael Finikiotis
Allopathic & Osteopathic Physicians|General Practice · PITTSBURGH, PA · NPI 1952374142
Verified facts
What the public records show
CMS Open Payments records show Michael Finikiotis received $59.76 in general payments during 2025 across 3 reported records.
Exact Sciences Corporation accounted for 67.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 544 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.54 | 67.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.22 | 32.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $59.76 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 11 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
544 | 113 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1464 | 411 |
| Levothyroxine Sodium | Levothyroxine Sodium | 839 | 216 |
| Lisinopril | Lisinopril | 643 | 179 |
| Amlodipine Besylate | Amlodipine Besylate | 574 | 162 |
| Losartan Potassium | Losartan Potassium | 553 | 156 |
| Eliquis | Apixaban | 544 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 531 | 171 |
| Omeprazole | Omeprazole | 487 | 151 |
| Tamsulosin Hcl | Tamsulosin Hcl | 400 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 372 | 107 |
| Gabapentin | Gabapentin | 293 | 80 |
| Escitalopram Oxalate | Escitalopram Oxalate | 278 | 72 |
| Simvastatin | Simvastatin | 266 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 263 | 74 |
| Sertraline Hcl | Sertraline Hcl | 234 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 227 | 73 |
| Metformin Hcl Er | Metformin Hcl | 226 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 70 |
| Furosemide | Furosemide | 220 | 66 |
| Potassium Chloride | Potassium Chloride | 212 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 209 | 54 |
| Alendronate Sodium | Alendronate Sodium | 193 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 186 | 54 |
| Famotidine | Famotidine | 184 | 60 |
| Metformin Hcl | Metformin Hcl | 183 | 56 |
| Finasteride | Finasteride | 167 | 46 |
| Carvedilol | Carvedilol | 159 | 42 |
| Trazodone Hcl | Trazodone Hcl | 156 | 45 |
| Synthroid | Levothyroxine Sodium | 154 | 41 |
| Jardiance | Empagliflozin | 142 | 30 |
| Montelukast Sodium | Montelukast Sodium | 128 | 30 |
| Allopurinol | Allopurinol | 122 | 35 |
| Xarelto | Rivaroxaban | 121 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 29 |
| Methylprednisolone | Methylprednisolone | 117 | 85 |
| Valsartan | Valsartan | 116 | 30 |
| Mirtazapine | Mirtazapine | 111 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 39 |
| Bupropion Xl | Bupropion Hcl | 101 | 23 |
| Celecoxib | Celecoxib | 99 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 95 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 20 |
| Lorazepam | Lorazepam | 93 | 41 |
| Atenolol | Atenolol | 91 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 27 |
| Ozempic | Semaglutide | 89 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 20 |
| Alprazolam | Alprazolam | 87 | 33 |
| Warfarin Sodium | Warfarin Sodium | 86 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 29 |
| Ezetimibe | Ezetimibe | 80 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 77 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 35 |
| Meloxicam | Meloxicam | 75 | 25 |
| Prednisone | Prednisone | 75 | 45 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 20 |
| Chlorthalidone | Chlorthalidone | 69 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 57 |
| Valacyclovir | Valacyclovir Hcl | 63 | 30 |
| Breo Ellipta | Fluticasone/Vilanterol | 60 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 60 | 22 |
| Azelastine Hcl | Azelastine Hcl | 59 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 46 |
| Bupropion Hcl Sr | Bupropion Hcl | 55 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 16 |
| Clonazepam | Clonazepam | 51 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | 12 |
| Spironolactone | Spironolactone | 50 | 14 |
| Nifedipine Er | Nifedipine | 49 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 48 | 18 |
| Azithromycin | Azithromycin | 46 | 37 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 40 |
| Donepezil Hcl | Donepezil Hcl | 45 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 14 |
| Diazepam | Diazepam | 44 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | 13 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Repatha Sureclick | Evolocumab | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 25 |
| Ondansetron Odt | Ondansetron | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 11 |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Cephalexin | Cephalexin | 36 | 25 |
| Ibuprofen | Ibuprofen | 36 | suppressed |
| Colchicine | Colchicine | 35 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 34 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 20 |
| Baclofen | Baclofen | 24 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 24 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Silodosin | Silodosin | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Dofetilide | Dofetilide | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 13 | 13 |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Symproic | Naldemedine Tosylate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | 12 |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Topamax | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $59.76 · 3 records | Exact Sciences Corporation | ABRYSVO, Cologuard Collection Kit, PREVNAR 20, The Cologuard Plus Collection Kit | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error